<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35294604</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1912</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>395</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Naunyn-Schmiedeberg's archives of pharmacology</Title>
          <ISOAbbreviation>Naunyn Schmiedebergs Arch Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antilipidemic ezetimibe induces regression of endometriotic explants in a rat model of endometriosis with its anti-inflammatory and anti-angiogenic effects.</ArticleTitle>
        <Pagination>
          <StartPage>673</StartPage>
          <EndPage>680</EndPage>
          <MedlinePgn>673-680</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00210-022-02226-2</ELocationID>
        <Abstract>
          <AbstractText>To assess the potential therapeutic role of antilipidemic ezetimibe on endometriosis in an experimental rat model. A standard experimental endometriosis model was created with 18 Whistar-Albino rats, and after 1 month, the sizes of the endometriotic explants were measured. The rats were randomized as study and control groups. A total of 1 mg/kg/day ezetimibe and 1 ml/kg/day saline were administered orally to the study and control groups respectively for 28 days. At the end of 28 days, the explants were measured again, excised, and sent for histopathologic assessment for expression of tumor necrosis factor-alpha (TNF-α) and vascular endothelial growth factor (VEGF) and number of mast cells. At the end of the study period, the size of the endometriotic explants decreased significantly in the study group; but not in the control group (from 145.3 ± 120.5 to 89.8 ± 60.1 vs 174.72 ± 88.3 to 87.65 ± 27.1 cm<sup>3</sup> respectively); however, the amount of post- and pretreatment differences in explant sizes was similar in the groups. The median TNF-α and VEGF levels were significantly lower in the ezetimibe group when compared to the control group (4 [3-4] vs 2 [1-3], p 0.029; 4 [3-4] vs 2 [2-3], p 0.002; respectively). And numbers of mast cells in all uterine layers were also lower in the ezetimibe group. Ezetimibe decreased the size of the endometriotic explants with its anti-inflammatory and anti-angiogenic properties. This agent alone or with combination of other agents may have a potential role in the treatment of endometriosis.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tapdıgova</LastName>
            <ForeName>Raziyya</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Mersin University, Mersin, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bayrak</LastName>
            <ForeName>Gülsen</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Histology and Embryology, Faculty of Medicine, Mersin University, Mersin, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yılmaz</LastName>
            <ForeName>Banu Coşkun</ForeName>
            <Initials>BC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Histology and Embryology, Faculty of Medicine, Mersin University, Mersin, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aytan</LastName>
            <ForeName>Hakan</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-2553-7715</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Mersin University, Mersin, Turkey. drhakanaytan@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Naunyn Schmiedebergs Arch Pharmacol</MedlineTA>
        <NlmUniqueID>0326264</NlmUniqueID>
        <ISSNLinking>0028-1298</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EOR26LQQ24</RegistryNumber>
          <NameOfSubstance UI="D000069438">Ezetimibe</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004715" MajorTopicYN="Y">Endometriosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069438" MajorTopicYN="N">Ezetimibe</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Endometriosis</Keyword>
        <Keyword MajorTopicYN="Y">Ezetimibe</Keyword>
        <Keyword MajorTopicYN="Y">Mast cell</Keyword>
        <Keyword MajorTopicYN="Y">TNF-alpha</Keyword>
        <Keyword MajorTopicYN="Y">VEGF</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>17</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35294604</ArticleId>
        <ArticleId IdType="doi">10.1007/s00210-022-02226-2</ArticleId>
        <ArticleId IdType="pii">10.1007/s00210-022-02226-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Aytan H, Caliskan AC, Demirturk F, Aytan P, Koseoglu DR (2007a) Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model. Aust N Z J Obstet Gynaecol 47:321–325</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1479-828X.2007.00744.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aytan H, Caglar P, Uygur D, Zergeroglu S, Batioglu S (2007b) Effect of the immunomodulator leflunomide on the induction of endometriosis in an experimental rat model. Fertil Steril 87:698–701</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2006.07.1527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burney RO, Giudice LC (2012) Pathogenesis and pathophysiology of endometriosis. Fertil Steril 98:511–519</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2012.06.029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolezelova E, Stein E, Derosa G, Maffioli P, Nachtigal P, Sahebkar A (2017) Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. Br J Clin Pharmacol 83:1380–1396</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcp.13250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efstathiou JA, Sampson DA, Levine Z et al (2005) Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 83:171–181</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2004.06.058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ezzet F, Krishna G, Wexler DB, Statkevich P, Kosoglou T, Batra VK (2001) A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 23:871–885</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0149-2918(01)80075-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrero S, Abbamonte LH, Anserini P, Remorgida V, Ragni N (2005) Future perspectives in the medical treatment of endometriosis. Obstet Gynecol Surv 60:817–826</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.ogx.0000189153.87365.dc</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hull ML, Charnock-Jones DS, Chan CL et al (2003) Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 88:2889–2899</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2002-021912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HO, Park CW, Hong SR (2003) Expression of CD44s, Ki-67, VEGF, and MMP-2 according to morphology of pelvic endometriosis. Fertil Steril 80(suppl):S224–S225</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0015-0282(03)01512-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB (2005) Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44:467–494</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00003088-200544050-00002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laschke MW, Elitzsch A, Scheuer C, Holstein JH, Vollmar B, Menger MD (2006) Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol 149:137–144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjp.0706857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li XX, Zhao L, Chang Y et al (2018) Ezetimibe prevents myocardial remodeling in an obese rat model by inhibiting inflammation. Acta Biochim Pol 65:465–470</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18388/abp.2018_2597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machado DE, Perini JA, de Mendonça EM, Branco JR, Rodrigues-Baptista KC, Alessandra-Perini J et al (2018) Clotrimazole is effective for the regression of endometriotic implants in a Wistar rat experimental model of endometriosis. Mol Cell Endocrinol 476:17–26</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mce.2018.04.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miura K, Ohnishi H, Morimoto N et al (2019) Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet. Cancer Sci 110:771–783</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.13902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nap AW, Dunselman GA, Griffioen AW, Mayo KH, Evers JL, Groothuis PG (2005) Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril 83:793–795</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2004.06.080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nisolle M, Casanas-Roux F, Anaf V, Mine JM, Donnez J (1993) Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 59:681–684</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0015-0282(16)55823-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oeckinghaus A, Ghosh S (2009) The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1(4):a000034. https://doi.org/10.1101/cshperspect.a000034</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a000034</ArticleId>
            <ArticleId IdType="pubmed">20066092</ArticleId>
            <ArticleId IdType="pmc">2773619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rafique S, Decherney AH (2017) Medical management of endometriosis. Clin Obstet Gynecol 60:485–496</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/GRF.0000000000000292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santulli P, Marcellin L, Noël J-C et al (2012) Sphingosine pathway deregulation in endometriotic tissues. Fertil Steril 97:904–911</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2011.12.051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibuya M (2006) Differential roles of vascular en dothelial growth factor receptor-1 and recep tor-2 in angiogenesis. J Biochem Mol Biol 39:469–478</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17002866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibuya M (2013) Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 153:13–19</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jb/mvs136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor HS, Alderman Iii M, D’Hooghe TM, Fazleabas AT, Duleba AJ (2017) Effect of simvastatin on baboon endometriosis. Biol Reprod 97:32–38</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/biolre/iox058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallée A, Lecarpentier Y (2020) Curcumin and endometriosis. Int J Mol Sci 21:2440</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21072440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vernon MW, Wilson EA (1985) Studies on the surgical induction of endometriosis in the rat. Fertil Steril 44:684–694</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0015-0282(16)48988-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Rokitansky KF. Ueber uterusdrüsen-neubildung in uterus-und ovarial-sarcomen. Druck von Carl Ueberreuter; 1860. 6 p</Citation>
        </Reference>
        <Reference>
          <Citation>Yilmaz B, Sucak A, Kilic S et al (2010a) Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9. Am J Obstet Gynecol 202(368):e1-8. https://doi.org/10.1016/j.ajog.2009.10.873</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajog.2009.10.873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yilmaz B, Ozat M, Kilic S et al (2010b) Atorvastatin causes regression of endometriotic implants in a rat model. Reprod Biomed Online 20:291–299</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rbmo.2009.11.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou WJ, Yang HL, Shao J, Mei J, Chang KK, Zhu R, Li MQ (2019) Anti-inflammatory cytokines in endometriosis. Cell Mol Life Sci 76:2111–2132</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-019-03056-x</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
